M. Cocchietto

发表

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin

A. Bergamo, G. Sava, L. Messori, 2003, Investigational New Drugs.

Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines

A. Bergamo, G. Sava, E. Alessio, 2003, Journal of Pharmacology and Experimental Therapeutics.

The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure

G. Sava, L. Candussio, S. Zorzet, 2015, JBIC Journal of Biological Inorganic Chemistry.

Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells

P. Veronesi, G. Sava, E. Masat, 2014, Experimental biology and medicine.

Down‐regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti‐metastatic ruthenium complex

A. Bergamo, G. Sava, E. Alessio, 1996, International journal of cancer.

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.

B. Keppler, P. Dyson, A. Bergamo, 2007, Dalton transactions.

Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration

G. Sava, S. Zorzet, M. Cocchietto, 2003, Investigational New Drugs.

Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

G. Pezzoni, A. Bergamo, G. Sava, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).

J. G. Haasnoot, E. Zangrando, A. Bergamo, 2004, Journal of Medicinal Chemistry.

Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

I. Tavernelli, U. Rothlisberger, P. Dyson, 2006 .

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

P. Dyson, G. Laurenczy, A. Bergamo, 2005, Journal of medicinal chemistry.

Intratumoral NAMI-A Treatment Triggers Metastasis Reduction, Which Correlates to CD44 Regulation and Tumor Infiltrating Lymphocyte Recruitment

M. Bacac, G. Sava, S. Zorzet, 2004, Journal of Pharmacology and Experimental Therapeutics.

Lysozyme-containing chitosan-coated alginate microspheres for oral immunisation

D. Voinovich, G. Sava, L. Zorzin, 2006 .

Response of MCa Mammary Carcinoma to Cisplatin and to Na[trans-RuCl4(DMSO)Im]

G. Sava, E. Alessio, M. Coluccia, 1994 .

Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

G. Sava, M. Cocchietto, 2000, Pharmacology & toxicology.

Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma

G. Sava, S. Zorzet, M. Cocchietto, 2001, Metal-based drugs.

A review on usnic acid, an interesting natural compound

G. Sava, P. Nimis, M. Cocchietto, 2002, Naturwissenschaften.

Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.

A. Bergamo, G. Sava, E. Alessio, 2000, The Journal of pharmacology and experimental therapeutics.

Vaccination trials of sea bass (Dicentrarchus labrax) against pasteurellosis using oral, intraperitoneal and immersion methods.

G. Giorgetti, M. Cocchietto, V. Ridolfi, 2005, Veterinaria italiana.

Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition.

A. Bergamo, G. Sava, E. Alessio, 1995, Chemico-biological interactions.

Bioavailability of metoclopramide from a new chewing gum device

D. Voinovich, L. Maggi, I. Grabnar, 2007 .

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

A. Bergamo, G. Sava, E. Alessio, 2002, European journal of cancer.

Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii

G. Sava, C. Manfrin, P. Giulianini, 2016 .

Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion

G. Sava, P. Spessotto, S. Zorzet, 2006, Journal of Pharmacology and Experimental Therapeutics.

Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

G. Sava, V. Scarcia, A. Furlani, 2004, European journal of cancer.

Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.

V. Brabec, A. Bergamo, G. Sava, 2015, Dalton transactions.

Inhibition of B 16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion

G. Sava, P. Spessotto, S. Zorzet, 2006 .

Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells

G. Sava, E. Alessio, V. Scarcia, 2005, Journal of Pharmacology and Experimental Therapeutics.

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

A. Bergamo, G. Sava, V. Scarcia, 2002, Cancer Chemotherapy and Pharmacology.

Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.

A. Bergamo, G. Sava, M. Carotenuto, 2001, Anticancer research.

Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.

G. Sava, E. Alessio, G. Mestroni, 1999, Anti-cancer drugs.

Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.

G. Sava, S. Zorzet, S. Pacor, 2013, Journal of inorganic biochemistry.

Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.

A. Bergamo, G. Sava, E. Alessio, 2002, International journal of oncology.

Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs.

G. Sava, M. Cocchietto, 2000, In vivo.

Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice

G. Sava, E. Alessio, R. Milanino, 2008, Pathology & Oncology Research.

Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.

A. Bergamo, G. Sava, M. Cocchietto, 1998, Chemico-biological interactions.

Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.

G. Sava, E. Alessio, G. Mestroni, 2000, Anticancer research.

Reduction of Lung Metastases by Na[trans-RuCl4(DMSO)Im] is not Coupled With the Induction of Chemical Xenogenization

A. Bergamo, G. Sava, E. Alessio, 1996, Metal-based drugs.

Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy.

G. Sava, M. Stebel, B. Fabris, 2008, Diabetes & metabolism.

Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions

R. Lapasin, G. Sava, P. Blasi, 2013, Journal of functional biomaterials.

Interaction of NAMI-A with the regulation of cell cycle progression of tumour cells.

A. Bergamo, G. Sava, S. Zorzet, 2000 .

Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.

A. Bergamo, G. Sava, E. Alessio, 2004, International journal of oncology.

The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure

G. Sava, L. Candussio, S. Zorzet, 2015, JBIC Journal of Biological Inorganic Chemistry.